AdipoGen Life Sciences

anti-FGF-23 (human), mAb (FG322-3)

CHF 190.00

In stock

AG-20A-0073-C05050 µgCHF 190.00

AG-20A-0073-C100100 µgCHF 320.00

Figure 1: Western blot analysis of human FGF23 using anti-FGF-23 (human), mAb (FG322-3) (Prod. No. AG-20A-0073) at 1:2,000 dilution.
1. Recombinant human FGF23 (FC protein).
2. Recombinant human cleavage-resistant FGF23 (R179Q).
3. Recombinant mouse FGF23 (Fc protein).
4. Recombinant human IL-17 (FC protein) (negative control).

Specifications / Handling

More Information
Product Details
Synonyms	Fibroblast Growth Factor 23; Tumor-derived Hypophosphatemia-inducing Factor
Product Type	Monoclonal Antibody
Properties
Clone	FG322-3
Isotype	Mouse IgG1κ
Immunogen/Antigen	Recombinant human FGF-23.
Application	ELISA: (direct and indirect: 1:2’000-1:5’000) Immunohistochemistry: (paraffin sections (1:100-1:500)) Western Blot: (1:2’000-1:5’000 using ECL. Suggested blocking and dilution buffer is PBST containing 0.05% Tween 20 and 5% skim milk. Suggested incubation time is 1 hour at room temperature). Optimal conditions must be determined individually for each application. Note: Tested on recombinant proteins and/or target-protein transfected cell lines in ELISA, Western Blot and/or IHC.
Crossreactivity	Human
Specificity	Recognizes human FGF-23. Does not cross-react with mouse FGF-23.
Purity Detail	Protein G-affinity purified.
Concentration	1mg/ml
Formulation	Liquid. 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.
Isotype Negative Control	Mouse IgG1 Isotype Control
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Use/Stability	Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

FGF-23 is a regulator of phosphate homeostasis. It upregulates EGR1 expression in the presence of KLBy. Acts directly on the parathyroid to decrease PTH secretion. Regulates the vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization. Defects in FGF-23 are the cause of autosomal dominant hypophosphataemic rickets (ADHR) and of hyperphosphatemic familial tumoral calcinosis (HFTC).

Product References

Tumor-associated FGF-23-induced hypophosphatemic rickets in children: a case report and review of the literature: M.A. Burkhardt, et al.; Pediatr. Nephrol. 30, 179 (2015)
Tumor-induced osteomalacia caused by phosphaturic mesenchymal tumor of the cervical spine: T. Nakamura, et al.; J. Orthop. Sci. 20, 765 (2015)
Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant: E. Shiba, et al.; Diagn. Pathol. 11, 26 (2016)
MicroRNA expression in a phosphaturic mesenchymal tumour: D. Green, et al.; Bone Rep. 7, 63 (2017)
A case of hyperparathyroidism which developed after resection of a fibroblast growth factor 23-producing tumor: K. Koikawa, et al.; Intern Med. 59, 2523 (2020)
Tumor-induced osteomalacia caused by an FGF23-secreting myopericytoma : Case report and literature review: N.M. Bushart, et al.; Orthopade 49, (2020)
Tumor induced osteomalacia - A long way toward correct diagnosis and management: L. Filipova, et al.; Bone Rep. 16, 101180 (2022)

Call	+41 61 926 6040
Fax	+41 61 926 6049